Pazopanib-d3 (hydrochloride)

Pazopanib-d3 (hydrochloride) (GW786034-d3 (hydrochloride) ) is deuterium labeled Pazopanib (Hydrochloride) . Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with an IC50 of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

Product Specifications

CAS Number

[2469755-67-5]

Product Name Alternative

GW786034-d3 (hydrochloride)

UNSPSC

12352005

Target

Autophagy; c-Fms; c-Kit; FGFR; Isotope-Labeled Compounds; PDGFR; VEGFR

Related Pathways

Autophagy; Others; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Smiles

O=S(C1=CC(NC2=NC=CC(N(C([2H])([2H])[2H])C3=CC4=NN(C)C(C)=C4C=C3)=N2)=CC=C1C)(N)=O.Cl

Molecular Formula

C21H21D3ClN7O2S

Molecular Weight

477.00

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Thakur A, et al. Pazopanib, a multitargeted tyrosine kinase inhibitor, reduces diabetic retinal vascular leukostasis and leakage. Microvasc Res. 2011 Nov;82 (3) :346-50.|[3]Harris PA, et al. Discovery of 5-[[4-[ (2,3-dimethyl-2H-indazol-6-yl) methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J Med Chem. 2008, 51 (15), 4632-4640.